These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7616748)

  • 1. Guidance for development of chemopreventive agents.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    J Cell Biochem Suppl; 1994; 20():25-31. PubMed ID: 7616748
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical programs in the development of similar biotherapeutic products: rationale and general principles.
    Berghout A
    Biologicals; 2011 Sep; 39(5):293-6. PubMed ID: 21911300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later.
    Avorn J; Kesselheim A; Sarpatwari A
    N Engl J Med; 2018 Sep; 379(12):1097-1099. PubMed ID: 30231220
    [No Abstract]   [Full Text] [Related]  

  • 5. International Conference on Harmonisation; guidance on the duration of chronic toxicity testing in animals (rodent and nonrodent toxicity testing); availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Jun; 64(122):34259-60. PubMed ID: 12356093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development plan: curcumin.
    J Cell Biochem Suppl; 1996; 26():72-85. PubMed ID: 9154169
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fundamental principles of clinical trials].
    Skarke C; Geisslinger G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):401-7. PubMed ID: 15830250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Cooperation on Harmonisation of Technical requirements for Approval of Veterinary Medicinal Products (VICH); final guidance on " Safety studies for veterinary drug residues in human food: reproduction toxicity testing" (VICH GL22); availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jan; 67(3):603-5. PubMed ID: 12365425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development plan: oltipraz.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():205-18. PubMed ID: 7616744
    [No Abstract]   [Full Text] [Related]  

  • 10. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ICH S5(R2) guideline for the testing of medicinal agents.
    Wise LD
    Methods Mol Biol; 2013; 947():1-11. PubMed ID: 23138891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Science and regulatory rituals associated with the drug development process.
    Versteegh LR
    Food Drug Law J; 1997; 52(2):155-61. PubMed ID: 10557552
    [No Abstract]   [Full Text] [Related]  

  • 13. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
    Leighton JK; Saber H; Reaman G; Pazdur R
    Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug evaluation and approval in the European Community.
    Marty M
    Eur J Cancer; 1996 Apr; 32A(4):574-5. PubMed ID: 8695255
    [No Abstract]   [Full Text] [Related]  

  • 15. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental product testing of biomedicines].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1131-2. PubMed ID: 25200486
    [No Abstract]   [Full Text] [Related]  

  • 19. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 20. [Methodological recommendations of the Regulatory Agencies].
    Torres F; Calvo G; Pontes C
    Med Clin (Barc); 2005 Dec; 125 Suppl 1():72-6. PubMed ID: 16464431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.